Illumina (NASDAQ:ILMN) Downgraded by StockNews.com to Hold

StockNews.com lowered shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research note released on Friday morning.

Other analysts also recently issued reports about the company. OTR Global reaffirmed a mixed rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen downgraded shares of Illumina from an outperform rating to a market perform rating and set a $144.00 target price on the stock. in a research note on Thursday, January 4th. HSBC cut shares of Illumina from a buy rating to a hold rating in a research note on Tuesday, January 16th. Robert W. Baird lifted their price target on shares of Illumina from $125.00 to $128.00 and gave the company a neutral rating in a research report on Friday. Finally, Barclays increased their price objective on Illumina from $85.00 to $100.00 and gave the stock an underweight rating in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $165.10.

Illumina Trading Down 4.9 %

ILMN stock opened at $117.93 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average of $130.33 and a two-hundred day moving average of $127.11. Illumina has a 12 month low of $89.00 and a 12 month high of $213.91.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.28% and a negative net margin of 28.71%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the business earned $0.08 earnings per share. The business’s revenue was down 1.0% compared to the same quarter last year. As a group, equities research analysts expect that Illumina will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.17% of the stock is owned by insiders.

Hedge Funds Weigh In On Illumina

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Trivant Custom Portfolio Group LLC lifted its stake in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 125 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Illumina during the 3rd quarter worth $30,000. VisionPoint Advisory Group LLC grew its stake in shares of Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new position in Illumina in the fourth quarter valued at $37,000. Finally, Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after buying an additional 132 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.